Huons KRX:243070KOSDAQ

휴온스 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked135since Sep 11

In Q2 2026, Huons reported revenue of ₩147bn, down 5.8% year on year, and operating profit of ₩2.9bn. Huons (휴온스) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 36 articles. The most common catalyst was clinical & approvals (19). It was most often mentioned alongside Chong Kun Dang Pharmaceutical, Hugel and Huons Global.

Huons quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩147bn-5.8%₩2.9bn
margin 2.0%
−₩1.1bn
Q1 2026₩142bn-2.7%−₩649m
margin −0.5%
₩191m
Q4 2025 derived₩165bn+12.7%₩9.8bn
margin 5.9%
₩9.8bn
Q3 2025₩154bn+4.7%₩9.9bn
margin 6.4%
₩8.2bn
Q2 2025₩156bn+4.7%₩13.1bn
margin 8.4%
₩11.8bn
Q1 2025₩146bn-1.3%₩12.8bn
margin 8.8%
₩12.3bn
Q4 2024 derived₩147bn+1.0%₩11.0bn
margin 7.5%
₩3.9bn
Q3 2024₩147bn+6.3%₩8.7bn
margin 5.9%
₩7.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Huons top stories 2 weeks, by number of outlets

  1. 1
    휴온스, UEG Week서 크론병 후보물질 비임상 결과 발표
    11 outlets · 11 articlesFirst report Oct 20 08:14 메디포뉴스Clinical trial
  2. 2
    휴온스, 유럽소화기학회서 크론병 신약 비임상 결과 공개
    6 outlets · 6 articlesFirst report Oct 20 08:35 한국경제Clinical trial
  3. 3
    휴온스, 크론병 치료 후보물질 비임상서 항섬유화 효과 확인
    3 outlets · 4 articlesFirst report Oct 20 08:10 메디파나뉴스
  4. 4
    휴온스, UEG서 크론병 장섬유화 겨냥 'HUC1A-626' 비임상 공개
    2 outlets · 2 articlesFirst report Oct 20 08:26 히트뉴스
  5. 5
    휴온스, 유럽 소화기학회서 ‘섬유협착성 크론병 치료제’ 비임상 결과 포스터 발표
    2 outlets · 2 articlesFirst report Oct 20 09:09 이투데이Clinical trial
  6. 6
    휴온스, 자체 신약 후보물질서 크론병 장 섬유화 억제 가능성 확인
    2 outlets · 2 articlesFirst report Oct 20 09:01 머니투데이

Latest Huons news Korean headlines